The role of combined Metformin and pharmaceutical molecules with anti-androgenic properties in the therapy of PCOS in adult women
Abstract
BACKGROUND: Polycystic ovary syndrome (PCOS) is a pathologic entity demonstrating heterogeneous clinical manifestations such as symptoms and signs of excessive androgen production (alopecia, acne, hirsutism and/or hyperandrogenemia) as well as oligomenorrhea (oligo- or an- ovulation) eventually accompanied by polycystic ovarian morphology. Metformin (an activator of adenosine monophosphate-activated protein kinase belonging to the biguanide class), used as treatment for type 2 diabetes mellitus, reduces glucose production of hepatic origin and increases its utilization, via insulin action, in liver and muscle. In PCOS patients, the use of metformin decreases hyperinsulinemia, improves menstrual cyclicity, promotes ovulation, facilitates implantation, increases pregnancy rates, and lowers modestly androgen concentrations. Pharmaceutical molecules with anti-androgenic properties block the androgen receptor and/or inhibit 5α-reductase activity. The latter catalyzes the testosterone to dihydrotestosterone transformation. These molecules are used as second-line treatment for skin disorders which accompany PCOS. They can also be used in combination with or as part of combined oral contraceptives (COCs) to reduce stigmata of hyperandrogenism. METHODS: The combined use of metformin and pharmaceutical molecules with anti-androgenic properties targets two different aspects of PCOS pathophysiology i.e. insulin resistance with the former and hyperandrogenism with the latter. Metformin…
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.